OC
BHVN

Oppenheimer & Co’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Oppenheimer & Co’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,310
Closed -$364K – 1375
2019
Q2 		$364K Buy
+8,310
New +$468K 0.01% 934

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Oppenheimer & Co's BHVN Position: Q3 2019 in Review

Oppenheimer & Co sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2019, closing a stake of 8,310 shares — an estimated $364K sold.

Oppenheimer & Co first reported a position in BHVN in Q2 2019 and held it in 1 quarter. The position peaked at $364K in Q2 2019. 184 funds tracked by Wall St. Rank hold BHVN as of Q3 2019.

  • Oppenheimer & Co reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2019 after selling out during the quarter.
  • Oppenheimer & Co sold 8,310 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2019, an estimated $364K.
  • Oppenheimer & Co first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 1 quarter.
  • Oppenheimer & Co's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $364K in Q2 2019.
  • 184 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2019.

Based on Oppenheimer & Co's 13F filing for Q3 2019, filed 31 Oct 2019.